China
Savolitinib; Gefitinib; EGFR-TKI; NSCLC; China; MET
bevacizumab, EGFR mutation, epidermal growth factor inhibitor, erlotinib, non-small-cell lung cancer, vascular endothelial growth factor inhibitor